Post-exposure prophylaxis for HIV infection: A clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 337-346

  Diaz Brito, Vicens ^a   León, Agathe ^a   Knobel, Hernando ^b   Peraire, Joaquim ^c   Domingo, Pere ^d   Clotet, Bonaventura ^e   Dalmau, David ^f   Cruceta, Anna ^a   Arnaiz, Joan Albert ^a   Gatell, Josep M ^a   García, Felipe ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; VERTIGO; VOMITING;

ADULT; ANTI-HIV AGENTS; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; LOPINAVIR; MALE; OLIGOPEPTIDES; POST-EXPOSURE PROPHYLAXIS; PYRIDINES; RITONAVIR; ZIDOVUDINE;

EID: 84860350870     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1955     Document Type: Article

References (29)

1. Tsai C-C, Folis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phpsophonylmethoxypropyl) adenine. Science 1995; 270:1197-1199.
2. Bourry O, Brochard P, Souquiere S, et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS 2009; 23:447-454.
3. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337:1485-1490. (Pubitemid 27495773)
4. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-1414. (Pubitemid 28516063)
5. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707-714. (Pubitemid 32171744)
6. Vives N, Almeda J, Contreras CA, Garcia F, Campins M, Casabona J. [Use of non-occupational HIV post-exposure prophylaxis in Spain (2001-2005)]. Enferm Infecc Microbiol Clin 2008; 26:546-551. Spanish.
7. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46-54. (Pubitemid 38067388)
8. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065-2073. (Pubitemid 39463360)
9. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-525. (Pubitemid 38420661)
10. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54:1-17.
11. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1-20.
12. Iribarren JA, Labarga P, Rubio R, et al. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected adults (October 2004)]. Enferm Infecc Microbiol Clin 2004; 22:564-642. Spanish. (Pubitemid 40070044)
13. Almeda J, Casabona J, Allepuz A, et al. [Recommendations for non-occupational postexposure HIV prophylaxis]. Enferm Infecc Microbiol Clin 2002; 20:391-400. Spanish. (Pubitemid 35315348)
14. Almeda J, Casabona J, Simon B, et al. Proposed recommendations for the management of HIV postexposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004; 9:35-40.
15. Puro V. Post-exposure prophylaxis for HIV infection. Italian Registry of Post-Exposure Prophylaxis. Lancet 2000; 355:1556-1557.
16. Parkin JM, Murphy M, Anderson J, El Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355:722-723. (Pubitemid 30107631)
17. Wang SA, Panlilio AL, Doi PA, White AD, Stek M, Jr., Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21:780-785. (Pubitemid 32010222)
18. Rabaud C, Bevilacqua S, Beguinot I, et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32:1494-1495. (Pubitemid 32424286)
19. Rabaud C, Burty C, Grandidier M, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis 2005; 40:303-305. (Pubitemid 40110678)
20. Quirino T, Niero F, Ricci E, et al. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000; 5:195-197.
21. Garcia F, Plana M, Mestre G, et al. Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis. Antivir Ther 2002; 7:195-197. (Pubitemid 36427145)
22. Landovitz RJ, Currier JS. Postexposure prophylaxis for HIV infection. N Engl J Med 2009; 361:1768-1775.
23. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
24. Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 2010; 24:2375-2380.
25. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008; 47:494-499. (Pubitemid 351366963)
26. Burty C, Prazuck T, Truchetet F, et al. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV. AIDS Patient Care STDS 2010; 24:1-3.
27. Puro V, Italian Registry of Antiretoviral Post-exposure Prophylaxis. Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS 2000; 14:2407-2408.
28. Siegel MO, Kan VL, Benator DA. Raltegravir for postexposure prophylaxis following occupational exposure to HIV. AIDS 2008; 22:2552-2553.
29. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16:397-405. (Pubitemid 34165371)